Supernus Pharmaceuticals, a former subsidiary of Shire with five product candidates in development for treatment of epilepsy, ADHD and depression, filed on Thursday with the SEC to raise up to $100 million in an initial public offering. The Rockville, MD-based company, which was spun off in 2005, booked $12 million in milestone and royalty payments for the 12 months ended September 30. Principal stockholders include New Enterprise Associates (45%), OrbiMed (18%), Abingworth Bioventures (18%) and Shire (7%). Supernus Pharmaceuticals plans to list on the NASDAQ under the symbol SUPN. Citi and Barclays Capital are the lead underwriters on the deal, for which pricing terms and timing were not disclosed.
